%0 Journal Article
%A Schwalbe, Edward C
%A Lindsey, Janet C
%A Danilenko, Marina
%A Hill, Rebecca M
%A Crosier, Stephen
%A Ryan, Sarra L
%A Williamson, Daniel
%A Castle, Jemma
%A Hicks, Debbie
%A Kool, Marcel
%A Milde, Till
%A Korshunov, Andrey
%A Pfister, Stefan M
%A Bailey, Simon
%A Clifford, Steven C
%T Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study.
%J Neuro-Oncology
%V 27
%N 1
%@ 1522-8517
%C Oxford
%I Oxford Univ. Press
%M DKFZ-2024-02020
%P 222–236
%D 2025
%Z Volume 27, Issue 1, January 2025, Pages 222–236
%X MYC/MYCN are the most frequent oncogene amplifications in medulloblastoma (MB) and its primary biomarkers of high-risk (HR) disease. However, while many patients' MYC(N)-amplified tumors are treatment-refractory, some achieve long-term survival. We therefore investigated clinicobiological heterogeneity within MYC(N)-amplified MB and determined its relevance for improved disease management.We characterized the clinical and molecular correlates of MYC- (MYC-MB; n = 64) and MYCN-amplified MBs (MYCN-MB; n = 95), drawn from >1600 diagnostic cases.Most MYC-MBs were molecular group 3 (46/58; 79
%K MYC amplification (Other)
%K MYCN amplification (Other)
%K medulloblastoma (Other)
%K survival (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39377358
%R 10.1093/neuonc/noae178
%U https://inrepo02.dkfz.de/record/293955